Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy

BACKGROUND: Alpha-synuclein (α-Syn) aggregation is the primary characteristic of synucleinopathies including Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). Immunotherapy targeting α-Syn has shown promising results in animal models of the disease. This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Nimmo, Jacqui T., Verma, Ajay, Dodart, Jean-Cosme, Wang, Chang Yi, Savistchenko, Jimmy, Melki, Ronald, Carare, Roxana O., Nicoll, James A. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702704/
https://www.ncbi.nlm.nih.gov/pubmed/33256825
http://dx.doi.org/10.1186/s13195-020-00727-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702704/
https://www.ncbi.nlm.nih.gov/pubmed/33256825
http://dx.doi.org/10.1186/s13195-020-00727-x

Ejemplares similares